Adagene published a medical research presentation outlining clinical progress for ADG126 (muzastotug), a masked anti-CTLA-4 antibody with FDA Fast Track status.
Interim results highlighted efficacy with low discontinuations in late-line MSS colorectal cancer patients without liver metastases.
Sanofi-backed plan included up to USD 25 million equity investment support for a randomized Phase 2 ADG126-pembrolizumab study in that subgroup.
Cash balance was about USD 128 million as of June 30, 2026; runway projected into late 2028.
ADAG•
